Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U06 Substudy 06B in previously treated advanced esophageal squamous cell carcinoma
2023-505189-26-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- Mar 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 14
01
Overview
Phase 2, open-label trial of sacituzumab tirumotecan, lenvatinib, pembrolizumab, mk-4830, paclitaxel and 1 more in Esophageal Squamous Cell Carcinoma (ESCC) (3 arms), sponsored by Merck & Co. Primary endpoints: Number of participants experiencing dose-limiting toxicities during safety lead-in phase, Number of participants who experienced an adverse event during safety lead-in phase and 2 more. Planned start Mar 2023; status: authorised.
02
Drugs
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on 2023-505189-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505189-26-00.